# Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors

> **NCT00471588** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 52 (actual)

## Conditions studied

- Obsessive-Compulsive Disorder

## Interventions

- **DRUG:** Pramipexole, Amisulpride

## Key facts

- **NCT ID:** NCT00471588
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471588, "Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00471588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*